Physician profile
Lindsey K Lear
NPI 1881824589
$7,576.29
in general payments reported to CMS, 2019-2025
25 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.40 · 2021: $11.36 · 2022: $1,179 · 2023: $1,023 · 2024: $3,403 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,668 · Travel and Lodging: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,668.15 |
| Travel and Lodging | $1,698.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $3,421.37 | 2022-2025 | |
| Alcon Vision LLC | $1,681.18 | 2022-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Bausch & Lomb Americas INC. | $481.79 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $470.97 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $272.12 | 2024-2025 | Xdemvy |
| Abbvie INC. | $233.54 | 2022-2025 | |
| Notal Vision, INC. | $173.28 | 2022 | |
| Dompe US, INC. | $168.62 | 2022-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $91.52 | 2022-2023 | Acthar |
| Horizon Therapeutics Plc | $86.00 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $79.16 | 2022-2023 | Tyrvaya |
| Ani Pharmaceuticals, INC. | $51.46 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $47.60 | 2024 | Tepezza |
| Thea Pharma INC. | $45.55 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $42.86 | 2024 | Ilevro, Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $40.76 | 2022 | |
| Glaukos Corporation | $39.55 | 2024 | Idose |
| Novartis Pharmaceuticals Corporation | $22.50 | 2022 | |
| Astellas Pharma US INC | $21.11 | 2023 | Izervay |
| Travere Therapeutics, INC. | $21.08 | 2023 | Cholbam |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $19.26 | 2023 | Acuvue |
| Eyevance Pharmaceuticals LLC | $18.69 | 2022 | |
| Sight Sciences, INC. | $15.56 | 2023 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Lear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.